{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:26:42Z","timestamp":1790879202718,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.neuint.2004.04.005","type":"journal-article","created":{"date-parts":[[2004,7,16]],"date-time":"2004-07-16T15:32:51Z","timestamp":1089991971000},"page":"1107-1112","source":"Crossref","is-referenced-by-count":79,"title":["Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin\/proteasome pathway"],"prefix":"10.1016","volume":"45","author":[{"given":"Hui-Chiu","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chun","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ju","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Jyh","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2004.04.005_BIB1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00001622-200211000-00007","article-title":"Proteasome inhibitors as new anticancer drugs","volume":"14","author":"Adams","year":"2002","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.neuint.2004.04.005_BIB2","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","article-title":"Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients","volume":"10","author":"Andreassi","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF03401830","article-title":"Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes","volume":"6","author":"Baron-Delage","year":"2000","journal-title":"Mol. Med."},{"key":"10.1016\/j.neuint.2004.04.005_BIB4","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuint.2004.04.005_BIB5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s004390050555","article-title":"Molecular analysis of survival motor neuron (SMN) and neuronal apoptosis inhibitory protein (NAIP) genes of spinal muscular atrophy patients and their parents","volume":"100","author":"Chang","year":"1997","journal-title":"Hum. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/(SICI)1097-4644(2000)77:34+<40::AID-JCB9>3.0.CO;2-6","article-title":"The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications","volume":"34","author":"Ciechanover","year":"2000","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.neuint.2004.04.005_BIB7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1042\/bst0311178","article-title":"Mechanisms controlling EGF receptor endocytosis and degradation","volume":"31","author":"Dikic","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuint.2004.04.005_BIB8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2014a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.neuint.2004.04.005_BIB9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0092-8674(00)80368-2","article-title":"The SMN\u2013SIP1 complex has an essential role in spliceosomal snRNP biogenesis","volume":"90","author":"Fischer","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2004.04.005_BIB10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/3030","article-title":"Differential SMN2 expression associated with SMA severity","volume":"20","author":"Gavrilov","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB11","doi-asserted-by":"crossref","first-page":"48937","DOI":"10.1074\/jbc.M107274200","article-title":"Degradation of p27(Kip1) at the G(0)\u2013G(1) transition mediated by a Skp2-independent ubiquitination pathway","volume":"276","author":"Hara","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuint.2004.04.005_BIB12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0093-7754(01)90033-8","article-title":"Novel therapies targeting the myeloma cell and its bone marrow microenvironment","volume":"28","author":"Hideshima","year":"2001","journal-title":"Semi. Oncol."},{"key":"10.1016\/j.neuint.2004.04.005_BIB13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB14","doi-asserted-by":"crossref","first-page":"I37","DOI":"10.1007\/s004150050555","article-title":"The role of SMN in spinal muscular atrophy","volume":"247","author":"Jablonka","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuint.2004.04.005_BIB15","doi-asserted-by":"crossref","first-page":"13312","DOI":"10.1073\/pnas.230364197","article-title":"Survival motor neuron protein modulates neuron-specific apoptosis","volume":"97","author":"Kerr","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuint.2004.04.005_BIB16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/1097-4547(20001101)62:3<346::AID-JNR4>3.0.CO;2-D","article-title":"Expression and subcellular localization of two isoforms of the survival motor neuron protein in different cell types","volume":"62","author":"La Bella","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuint.2004.04.005_BIB17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s100480000090","article-title":"The survival motor neuron (SMN) protein: effect of exon loss and mutation on protein localization","volume":"3","author":"Le","year":"2000","journal-title":"Neurogenetics"},{"key":"10.1016\/j.neuint.2004.04.005_BIB18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2004.04.005_BIB19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB20","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/j.1460-2075.1996.tb00725.x","article-title":"A novel nuclear structure containing the survival of moter neurons protein","volume":"15","author":"Liu","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.neuint.2004.04.005_BIB21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","article-title":"The spinal muscular atrophy disease gene product, SMN, and associated protein SIP1 are in a complex with spliceosomal snRNP proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2004.04.005_BIB22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB23","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/hmg\/9.16.2451","article-title":"Animal models of spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB24","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematological malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuint.2004.04.005_BIB25","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1136\/jmg.15.6.409","article-title":"Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy","volume":"15","author":"Pearn","year":"1978","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(80)90847-8","article-title":"Classification of spinal muscular atrophies","volume":"1","author":"Pearn","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2004.04.005_BIB27","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.neuint.2004.04.005_BIB28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00019052-200110000-00012","article-title":"Molecular mechanisms in spinal muscular atrophy: models and perspectives","volume":"14","author":"Sendtner","year":"2001","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuint.2004.04.005_BIB29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jnci\/95.12.845","article-title":"First proteasome inhibitor approved for multiple myeloma","volume":"95","author":"Twombly","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.neuint.2004.04.005_BIB30","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/hmg\/11.22.2751","article-title":"Involvement of survival motor neuron (SMN) protein in cell death","volume":"11","author":"Vyas","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2004.04.005_BIB31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum. Mut."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018604000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018604000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T15:53:36Z","timestamp":1585842816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018604000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0197018604000907"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2004.04.005","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}